Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
1.470
+0.010 (0.68%)
At close: Oct 8, 2025, 4:00 PM EDT
1.470
0.00 (0.00%)
After-hours: Oct 8, 2025, 7:52 PM EDT
Company Description
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics.
It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.
The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022.
Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Revelation Biosciences, Inc.
Country | United States |
Founded | 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 9 |
CEO | James Rolke |
Contact Details
Address: 4660 La Jolla Village Drive, Suite 100 San Diego, California 92122 United States | |
Phone | (650) 800-3717 |
Website | revbiosciences.com |
Stock Details
Ticker Symbol | REVB |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001810560 |
CUSIP Number | 76135L705 |
ISIN Number | US76135L7055 |
Employer ID | 84-3898466 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
James M. Rolke | Chairman and Chief Executive Officer |
Chester Stanley Zygmont III | Chief Financial Officer and Corporate Secretary |
Sandra Vedrick | Vice President of Human Resources and Investor Relations |
Carol Odle | Senior Director of Clinical Projects |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Sep 30, 2025 | EFFECT | Notice of Effectiveness |
Sep 30, 2025 | 424B3 | Prospectus |
Sep 30, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
Sep 22, 2025 | DEF 14A | Other definitive proxy statements |
Sep 16, 2025 | S-3 | Registration statement under Securities Act of 1933 |
Sep 15, 2025 | 8-K | Current Report |
Sep 12, 2025 | PRE 14A | Other preliminary proxy statements |
Sep 9, 2025 | 8-K | Current Report |
Aug 8, 2025 | 8-K | Current Report |
Aug 8, 2025 | 10-Q | Quarterly Report |